| Title |
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, February 2012
|
| DOI | 10.2147/dmso.s28387 |
| Pubmed ID | |
| Authors |
Leigh MacConell, Carl Brown, Kate Gurney, Jenny Han |
| Abstract |
Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety profile of exenatide twice daily and to compare its profile with that of a pooled comparator (placebo and insulin) in patients with type 2 diabetes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 2% |
| France | 1 | 1% |
| Brazil | 1 | 1% |
| United Kingdom | 1 | 1% |
| Singapore | 1 | 1% |
| Russia | 1 | 1% |
| Spain | 1 | 1% |
| Unknown | 86 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 17% |
| Researcher | 14 | 15% |
| Other | 13 | 14% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Bachelor | 8 | 9% |
| Other | 16 | 17% |
| Unknown | 17 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 50% |
| Nursing and Health Professions | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Agricultural and Biological Sciences | 4 | 4% |
| Computer Science | 3 | 3% |
| Other | 6 | 6% |
| Unknown | 23 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#837
of 1,182 outputs
Outputs of similar age
#206,034
of 254,308 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#3
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,182 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,308 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.